A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine

Trial Profile

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Telcagepant (Primary)
  • Indications Menstrual migraine
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 02 Oct 2014 Trial focus has been changed from efficacy to efficacy and tolerability as reported by ClinicalTrials.gov record.
    • 07 Jul 2012 Actual patient number is 4582 according to ClinicalTrials.gov.
    • 31 Mar 2012 Additional locations (Denmark, Finland, Germany, Netherlands, Sweden and United Kingdom) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top